Redeye comments on the recent news regarding Integrum’s partnership with Intelerad.
Q4 report due Thursday, 13 February We cut adj. EBITA 4%/3%/3% on '24e/'25e/'26e Share is trading at...
Duell reported Q1 net sales at EUR 28.3m, just surpassing our forecast of EUR 27.
Xplora does not meet the 90% threshold, so delisting and forced buy-out plans are on hold unless fur...
Safello pre-announced key metrics for its Q4 2024 report due 21/02/2025.
Peer and competitor in Finland, HKFoods is out with a positive profit warning stating its 2024 compa...
Redeye makes a brief comment on today’s news of the CEO replacement.
Redeye provides a brief comment on Flexion Mobile’s new agreement with King, under which Flexion Mob...
Q4e: Clean paper EBIT of ~PLN 10m Paper prices down, demand muted Fair value range of SEK 40-80 Thi...
Q4e: clean EBIT of ~SEK -90m, Q1 should be better Pulp prices down, but hikes announced Fair value r...
Preliminary Q4 EBITA ~40% below FactSet consensus We expect consensus to cut '25 EBITA by ~15% and '...
Xplora Technologies AS announced a public offer on September 26, 2024, to acquire all shares in Doro...
Redeye comments on Nanologica following the annonucement of a SEK8.
Redeye comments on Ortoma’s announcement yesterday that they have submitted a supplemental 510(k) to...
Redeye comments on CLS’s recap of 2024 and outlook for 2025-2026.
Redeye comments on SciBase’s announcement of its preliminary results for the capital raise this morn...
Redeye leaves a comment following OncoZenge’s announcement yesterday of having entered into a non-bi...
Ahead of Elanders' Q4 report, we lower 2024E adjusted EBITA by 2%, while we raise 2025E-26E by 2%.
Redeye comments on Iconovo’s collaboration with Lonza to develop a reformulated obesity treatment.
Redeye expects a stable Q4 report from Sdiptech but with tough comparables weighing negatively.
